[
  {
    "ts": null,
    "headline": "Treatment with tirzepatide in adults with pre-diabetes and obesity or overweight resulted in sustained weight loss and nearly 99% remained diabetes-free at 176 weeks",
    "summary": "Eli Lilly and Company (NYSE: LLY) announced today detailed results from the Phase 3 SURMOUNT-1 three-year study (176-week treatment period), the longest completed study to date of tirzepatide. Weekly tirzepatide (Zepbound® and Mounjaro®) injections (pooled 5 mg, 10 mg, 15 mg doses) significantly reduced the risk of progression to type 2 diabetes in adults with pre-diabetes and obesity or overweight, compared with placebo, over 176 weeks. Tirzepatide demonstrated sustained average weight loss of",
    "url": "https://finnhub.io/api/news?id=8aef02ab8a9d6d38121e09bac57afa1d67cb6871c356331b27cfe524ddebbb0b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731535500,
      "headline": "Treatment with tirzepatide in adults with pre-diabetes and obesity or overweight resulted in sustained weight loss and nearly 99% remained diabetes-free at 176 weeks",
      "id": 131342239,
      "image": "https://media.zenfs.com/en/prnewswire.com/f3aaa8410f59c3eccd5d187ecffbd6ee",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly and Company (NYSE: LLY) announced today detailed results from the Phase 3 SURMOUNT-1 three-year study (176-week treatment period), the longest completed study to date of tirzepatide. Weekly tirzepatide (Zepbound® and Mounjaro®) injections (pooled 5 mg, 10 mg, 15 mg doses) significantly reduced the risk of progression to type 2 diabetes in adults with pre-diabetes and obesity or overweight, compared with placebo, over 176 weeks. Tirzepatide demonstrated sustained average weight loss of",
      "url": "https://finnhub.io/api/news?id=8aef02ab8a9d6d38121e09bac57afa1d67cb6871c356331b27cfe524ddebbb0b"
    }
  },
  {
    "ts": null,
    "headline": "Amgen Rebounds. But Do Eli Lilly And Viking Therapeutics Now Have The Upper Hand?",
    "summary": "Amgen stock rebounded Wednesday, shaking off \"overdone\" fears that its monthly weight-loss shot causes excessive bone mineral density loss.",
    "url": "https://finnhub.io/api/news?id=d87b2705646608122bb5d3495676bd18c12ee054e10aed77026f78633c92a41f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731516902,
      "headline": "Amgen Rebounds. But Do Eli Lilly And Viking Therapeutics Now Have The Upper Hand?",
      "id": 131327826,
      "image": "",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Amgen stock rebounded Wednesday, shaking off \"overdone\" fears that its monthly weight-loss shot causes excessive bone mineral density loss.",
      "url": "https://finnhub.io/api/news?id=d87b2705646608122bb5d3495676bd18c12ee054e10aed77026f78633c92a41f"
    }
  },
  {
    "ts": null,
    "headline": "Tracking Jeremy Grantham's GMO Capital Portfolio - Q3 2024 Update",
    "summary": "GMOâs 13F portfolio increased to $31.91B in Q3 2024. Click here to read more about the holdings and trades of GMO Capital Portfolio.",
    "url": "https://finnhub.io/api/news?id=1f10612cc8dd076b517497a7701346c351e530bf49e662e6f9e4366aee31e2cd",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731523255,
      "headline": "Tracking Jeremy Grantham's GMO Capital Portfolio - Q3 2024 Update",
      "id": 131336623,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/186805810/image_186805810.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "GMOâs 13F portfolio increased to $31.91B in Q3 2024. Click here to read more about the holdings and trades of GMO Capital Portfolio.",
      "url": "https://finnhub.io/api/news?id=1f10612cc8dd076b517497a7701346c351e530bf49e662e6f9e4366aee31e2cd"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly Say Most Tirzepatide Users Remained Diabetes-Free at 176 Weeks",
    "summary": "Eli Lilly Say Most Tirzepatide Users Remained Diabetes-Free at 176 Weeks",
    "url": "https://finnhub.io/api/news?id=112125188496e3acc5ab6efbf9d5c5c4c70eb0eb0e5070317fdfebfc64b68e08",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731520140,
      "headline": "Eli Lilly Say Most Tirzepatide Users Remained Diabetes-Free at 176 Weeks",
      "id": 131413514,
      "image": "",
      "related": "LLY",
      "source": "MarketWatch",
      "summary": "Eli Lilly Say Most Tirzepatide Users Remained Diabetes-Free at 176 Weeks",
      "url": "https://finnhub.io/api/news?id=112125188496e3acc5ab6efbf9d5c5c4c70eb0eb0e5070317fdfebfc64b68e08"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly & Co. stock underperforms Wednesday when compared to competitors",
    "summary": "Eli Lilly & Co. stock underperforms Wednesday when compared to competitors",
    "url": "https://finnhub.io/api/news?id=962586d892a5129e5e6b472b48250e3c319e86ba39672e0a1cfac6ad21eba807",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731515580,
      "headline": "Eli Lilly & Co. stock underperforms Wednesday when compared to competitors",
      "id": 131413515,
      "image": "",
      "related": "LLY",
      "source": "MarketWatch",
      "summary": "Eli Lilly & Co. stock underperforms Wednesday when compared to competitors",
      "url": "https://finnhub.io/api/news?id=962586d892a5129e5e6b472b48250e3c319e86ba39672e0a1cfac6ad21eba807"
    }
  },
  {
    "ts": null,
    "headline": "Altimmune: Pemvidutide As MASH Drug Could Provide Competitive Edge",
    "summary": "Altimmuneâs Pemvidutide aims for Phase 2b MASH study results in 2025. See why ALT stock could surge with the global obesity market expected to hit $200 billion.",
    "url": "https://finnhub.io/api/news?id=2d1d40faf6d0a586ffb8efcb5a87644951826ddc5a16ca977a942271535a0fd1",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731512622,
      "headline": "Altimmune: Pemvidutide As MASH Drug Could Provide Competitive Edge",
      "id": 131332720,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2165862291/image_2165862291.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Altimmuneâs Pemvidutide aims for Phase 2b MASH study results in 2025. See why ALT stock could surge with the global obesity market expected to hit $200 billion.",
      "url": "https://finnhub.io/api/news?id=2d1d40faf6d0a586ffb8efcb5a87644951826ddc5a16ca977a942271535a0fd1"
    }
  },
  {
    "ts": null,
    "headline": "Why Eli Lilly’s CEO says failing faster is essential to the company’s success",
    "summary": "For Eli Lilly CEO Dave Ricks, speeding up the drug discovery process is essential to success.",
    "url": "https://finnhub.io/api/news?id=3f0ed099726c720ac441cfdccd59a8e25b9389c48807dfffac8c543efac6a21c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731510911,
      "headline": "Why Eli Lilly’s CEO says failing faster is essential to the company’s success",
      "id": 131328221,
      "image": "https://s.yimg.com/ny/api/res/1.2/EvWzqTi2AgIP_0rqzYoGWw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD04MDA-/https://media.zenfs.com/en/fortune_175/95bdc985302ac2e4ccc0d855b05561e7",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "For Eli Lilly CEO Dave Ricks, speeding up the drug discovery process is essential to success.",
      "url": "https://finnhub.io/api/news?id=3f0ed099726c720ac441cfdccd59a8e25b9389c48807dfffac8c543efac6a21c"
    }
  },
  {
    "ts": null,
    "headline": "Hims & Hers launches GLP-1 tracker in response to FDA's shortage decision",
    "summary": "Hims & Hers is launching a tracker of GLP-1 shortages to push back against the FDA's recent moves to end compounding copycats of the blockbuster drugs.",
    "url": "https://finnhub.io/api/news?id=2aee0c47484da1c38255c1eb19c95b56e39718dd22723167e905f5cfa0ee9f0c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731509298,
      "headline": "Hims & Hers launches GLP-1 tracker in response to FDA's shortage decision",
      "id": 131329300,
      "image": "https://s.yimg.com/ny/api/res/1.2/7y4Q8mY4RQ_CMDSmsAG2SA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD04MDA-/https://s.yimg.com/os/creatr-uploaded-images/2024-10/312f6070-917e-11ef-adff-2720c0a47116",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Hims & Hers is launching a tracker of GLP-1 shortages to push back against the FDA's recent moves to end compounding copycats of the blockbuster drugs.",
      "url": "https://finnhub.io/api/news?id=2aee0c47484da1c38255c1eb19c95b56e39718dd22723167e905f5cfa0ee9f0c"
    }
  },
  {
    "ts": null,
    "headline": "Hims & Hers launches GLP-1 shortage tracker in its battle with the FDA",
    "summary": "Hims & Hers is launching a tracker of GLP-1 shortages to push back against the FDA's recent moves to end compounding copycats of the blockbuster drugs.",
    "url": "https://finnhub.io/api/news?id=f9e5f1e485842337eaf65731d4eded16e04a8cd88996ae61577bd971c98ecb28",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731509298,
      "headline": "Hims & Hers launches GLP-1 shortage tracker in its battle with the FDA",
      "id": 131325819,
      "image": "https://s.yimg.com/ny/api/res/1.2/7y4Q8mY4RQ_CMDSmsAG2SA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD04MDA-/https://s.yimg.com/os/creatr-uploaded-images/2024-10/312f6070-917e-11ef-adff-2720c0a47116",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Hims & Hers is launching a tracker of GLP-1 shortages to push back against the FDA's recent moves to end compounding copycats of the blockbuster drugs.",
      "url": "https://finnhub.io/api/news?id=f9e5f1e485842337eaf65731d4eded16e04a8cd88996ae61577bd971c98ecb28"
    }
  },
  {
    "ts": null,
    "headline": "Did Viking Therapeutics Just Say \"Checkmate\" To Eli Lilly?",
    "summary": "Viking Therapeutics just revealed a new plan that could make waves in the weight loss industry.",
    "url": "https://finnhub.io/api/news?id=b69f31eff0dd3a47ada8ae35ea57750dbaf7629e3d14978e6dd8789261f5c447",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731509100,
      "headline": "Did Viking Therapeutics Just Say \"Checkmate\" To Eli Lilly?",
      "id": 131325821,
      "image": "https://g.foolcdn.com/editorial/images/795713/gettyimages-1978065812-3.jpg",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Viking Therapeutics just revealed a new plan that could make waves in the weight loss industry.",
      "url": "https://finnhub.io/api/news?id=b69f31eff0dd3a47ada8ae35ea57750dbaf7629e3d14978e6dd8789261f5c447"
    }
  },
  {
    "ts": null,
    "headline": "Harding Loevner International Equity ADR Q3 2024 Report",
    "summary": "Harding Loevner International Equity ADR composite rose 9.2%,  gross, in Q3 2024, outpacing the 8.2% gain of the MSCI All Country ex US Index. Click here to read more.",
    "url": "https://finnhub.io/api/news?id=e170b3fd96d7bc8619610a77d31894c44660819fe9929a9fbe18f1c232e966aa",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731492300,
      "headline": "Harding Loevner International Equity ADR Q3 2024 Report",
      "id": 131325002,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1019729218/image_1019729218.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Harding Loevner International Equity ADR composite rose 9.2%,  gross, in Q3 2024, outpacing the 8.2% gain of the MSCI All Country ex US Index. Click here to read more.",
      "url": "https://finnhub.io/api/news?id=e170b3fd96d7bc8619610a77d31894c44660819fe9929a9fbe18f1c232e966aa"
    }
  },
  {
    "ts": null,
    "headline": "2 S&P 500 Dividend Stocks That Could Soar 30% or More, According to a Pair of Wall Street Analysts",
    "summary": "If Wall Street's right, investors will get a lot more than just rising dividend payments from this pair.",
    "url": "https://finnhub.io/api/news?id=c3e6c189602e20338cb050cb7eb41f010b452f691b3fe13bd28c6c7a438eec00",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731491820,
      "headline": "2 S&P 500 Dividend Stocks That Could Soar 30% or More, According to a Pair of Wall Street Analysts",
      "id": 131325823,
      "image": "https://g.foolcdn.com/editorial/images/796326/investor-individual-stock-charts-getty.jpg",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "If Wall Street's right, investors will get a lot more than just rising dividend payments from this pair.",
      "url": "https://finnhub.io/api/news?id=c3e6c189602e20338cb050cb7eb41f010b452f691b3fe13bd28c6c7a438eec00"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson: Tracking Well Above The Industry",
    "summary": "Johnson & Johnson shows strong progress in oncology with Darzalex sales and regulatory filings, leading to a 'Buy' rating from financial writer. Read more here.",
    "url": "https://finnhub.io/api/news?id=b93cf744417e6816b73bb9510095e2913406cda0e8427554ff425e4123bc4232",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731489024,
      "headline": "Johnson & Johnson: Tracking Well Above The Industry",
      "id": 131324406,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1413108793/image_1413108793.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Johnson & Johnson shows strong progress in oncology with Darzalex sales and regulatory filings, leading to a 'Buy' rating from financial writer. Read more here.",
      "url": "https://finnhub.io/api/news?id=b93cf744417e6816b73bb9510095e2913406cda0e8427554ff425e4123bc4232"
    }
  },
  {
    "ts": null,
    "headline": "TRex Bio raises $84M to compete in crowded immune drug field",
    "summary": "The California biotech has drawn partnerships with Eli Lilly and J&J on the promise of its approach to rebalancing the immune system.",
    "url": "https://finnhub.io/api/news?id=177ea697e2e1dc5f46ef27e884ed009d8ec3a86b5dd10d151539c6e93100ae97",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731481200,
      "headline": "TRex Bio raises $84M to compete in crowded immune drug field",
      "id": 131325824,
      "image": "https://imgproxy.divecdn.com/YK0ND5sRtkoQ3E8WppaIm-CXH-YmLxW22mIxzInyYIU/g:ce/rs:fit:770:435/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9Kb2huc3Rvbl9Fcndpbl9DRU9fVFJleEJpb18yMDI0X2NvcHkuanBlZw==.webp",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The California biotech has drawn partnerships with Eli Lilly and J&J on the promise of its approach to rebalancing the immune system.",
      "url": "https://finnhub.io/api/news?id=177ea697e2e1dc5f46ef27e884ed009d8ec3a86b5dd10d151539c6e93100ae97"
    }
  },
  {
    "ts": null,
    "headline": "Shelton International Select Equity Fund Q3 2024 Commentary",
    "summary": "For Q3 2024, the Shelton Capital International Select Fund returned 7.91%, underperforming the MSCI AC World ex-US index. Click here to read the full fund letter.",
    "url": "https://finnhub.io/api/news?id=8f3f50e6a526282d150e1ec8b574d6826f2746017f60da1ad2cecd19437d324c",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731475200,
      "headline": "Shelton International Select Equity Fund Q3 2024 Commentary",
      "id": 131320688,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/96502248/image_96502248.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "For Q3 2024, the Shelton Capital International Select Fund returned 7.91%, underperforming the MSCI AC World ex-US index. Click here to read the full fund letter. ",
      "url": "https://finnhub.io/api/news?id=8f3f50e6a526282d150e1ec8b574d6826f2746017f60da1ad2cecd19437d324c"
    }
  }
]